The DOI matches its Crossref record.
Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice
Open accessAbstract
Huntington disease (HD) is caused by an expansion of the polyglutamine (polyQ) repeat (>37Q) in huntingtin (htt), and age of onset is inversely correlated with the length of the polyQ repeat. Mutant htt with expanded polyQ is ubiquitously expressed in various types of cells, including glia, but causes selective neurodegeneration. Our recent study demonstrated that expression of the N-terminal mutant htt with a large polyQ repeat (160Q) in astrocytes is sufficient to induce neurological symptoms in mice (Bradford, J., Shin, J. Y., Roberts, M., Wang, C. E., Li, X.-J., and Li, S. H. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 22480-22485). Because glia-neuron interactions are critical for maintaining the normal function and survival of neurons in the brain and because mutant htt is more abundant in neurons than in glial cells, it is important to investigate whether glial htt can still contribute to HD pathology when mutant htt is abundantly expressed in neuronal cells. We generated transgenic mice that express mutant htt with 98Q in astrocytes. Unlike our recently generated htt-160Q transgenic mice, htt-98Q mice do not show obvious neurological phenotypes, suggesting that the length of the polyQ repeat determines the severity of glial dysfunction. However, htt-98Q mice show increased susceptibility to glutamate-induced seizure. Mice expressing mutant htt in astrocytes were mated with N171-82Q mice that express mutant htt primarily in neuronal cells. Double transgenic mice expressing mutant htt in both neuronal and glial cells display more severe neurological symptoms and earlier death than N171-82Q mice. These findings indicate a role of glial mutant htt in exacerbating HD neuropathology and underscore the importance of improving glial function in treating HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Astrocyte–neuron metabolic relationships: for better and for worse
Allaman, I., Bélanger, M., & Magistretti, P. J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2010.12.001 · Cited by 639
Tong, X., Ao, Y., Faas, G. C., Nwaobi, S. E., Xu, J., Haustein, M. D., Anderson, M. A., Mody, I., Olsen, M. L., Sofroniew, M. V., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3691 · Cited by 592
Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies
Jimenez-Sanchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 507
Astrocytes in Neurodegenerative Disease: Table 1.
Phatnani, H., & Maniatis, T. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020628 · Cited by 420
Molecular mechanisms of ferroptosis and their involvement in brain diseases
Costa, I., Barbosa, D. J., Benfeito, S., Silva, V., Chavarria, D., Borges, F., Remião, F., & Silva, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108373 · Cited by 402
Role of Estrogen and Other Sex Hormones in Brain Aging. Neuroprotection and DNA Repair
Zárate, S., Stevnsner, T., & Gredilla, R. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00430 · Cited by 285
Probing the Complexities of Astrocyte Calcium Signaling
Shigetomi, E., Patel, S., & Khakh, B. S. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.01.003 · Cited by 268
McBride, J. L., Pitzer, M. R., Boudreau, R. L., Dufour, B., Hobbs, T., Ojeda, S. R., & Davidson, B. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.219 · Cited by 247
Jiang, R., Diaz-Castro, B., Looger, L. L., & Khakh, B. S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3693-15.2016 · Cited by 237
Chen, C., Jiang, P., Xue, H., Peterson, S. E., Tran, H. T., McCann, A. E., Parast, M. M., Li, S., Pleasure, D. E., Laurent, L. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms5430 · Cited by 219
Self-citationAberrant iPSC-derived human astrocytes in Alzheimer's disease
Jones, V. C., Atkinson-Dell, R., Verkhratsky, A., & Mohamet, L. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.89 · Cited by 186
The Role of the Immune System in Huntington’s Disease
Ellrichmann, G., Reick, C., Saft, C., & Linker, R. A. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/541259 · Cited by 155
Microglial activation in the pathogenesis of Huntington's disease
Yang, H.-M., Yang, S., Huang, S.-S., Tang, B.-S., & Guo, J.-F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00193 · Cited by 151
Valenza, M., Marullo, M., Di Paolo, E., Cesana, E., Zuccato, C., Biella, G., & Cattaneo, E. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.162 · Cited by 133
Miguez, A., García-Díaz Barriga, G., Brito, V., Straccia, M., Giralt, A., Ginés, S., Canals, J. M., & Alberch, J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv218 · Cited by 126
Glia in neurodegeneration: Drivers of disease or along for the ride?
Gleichman, A. J., & Carmichael, S. T. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104957 · Cited by 90
Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Jia, Q., Li, S., Li, X.-J., & Yin, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088124 · Cited by 70
“For example, the mutant HTT expressed in glial cells, primarily astrocytes in HDmouse models, could reduce their neuroprotective function (9, 10).”
BackgroundSelf-citationMerienne, N., Douce, J. L., Faivre, E., Déglon, N., & Bonvento, G. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00106 · Cited by 58
“…in Cellular Neuroscience www.frontiersin.org July 2013 | Volume 7 | Article 106 | 7 “fncel-07-00106” — 2013/7/3 — 20:28 — page 8 — #8 2009), spinocerebellar ataxia 7 (Custer et al., 2006), HD (Gu et al., 2005; Bradford et al., 2009, 2010), and taupathies (Forman et al., 2005; Dabir et al., 2006).”
Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes
Chen, L.-L., Wu, J.-C., Wang, L.-H., Wang, J., Qin, Z.-H., Difiglia, M., & Lin, F. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.162 · Cited by 26
“In addition, mutant Htt expressed in glial cells could exacerbate neurological symptoms in HD transgenic mice, so the role of glial cells in HD neuropathology should not be neglected [5] .”
On astrocyte-neuron interactions: broad insights from the striatum
Khakh, B. S. (2025) · Neuron · doi:10.1016/j.neuron.2025.08.009 · Cited by 23
The long and the short of aberrant ciliogenesis in Huntington disease
Liu, J.-P., & Zeitlin, S. O. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60243 · Cited by 19
Stanek, L. M., Bu, J., & Shihabuddin, L. S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.015 · Cited by 15
Neuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Metadata
- Authors
- Bradford, J., Shin, J.-Y., Roberts, M., Wang, C.-E., Sheng, G., Li, S., & Li, X.-J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 285
- Issue
- 14
- Pages
- 10653-10661
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1993321996
- Cited by
- 164
- References
- 0
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.